The Priority Review

The stream · Daily digest

The stream: Friday, October 2, 2026

21 briefs from ClinicalTrials.gov, FDA and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 16

  1. Intra-Cellular Therapies registers JNJ-99245354 (ITI-1284) in generalized anxiety disorder

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 705 participants and has a planned start date of September 30, 2026, with a primary completion date of September 20, 2030.

    Source: ClinicalTrials.gov registry record, October 2, 2026

  2. Boehringer Ingelheim registers study of survodutide in overweight or obesity without diabetes

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The Phase IIIb, open-label study plans to enroll 350 participants, with a planned start date of November 7, 2026 and a primary completion date of June 25, 2028.

    Source: ClinicalTrials.gov registry record, October 2, 2026

  3. Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis

    The study, led by Jiankuan (Suzhou) Biotechnology Company Limited, plans to enroll 590 participants and begin on October 15, 2026. It is to evaluate different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs.

    Source: ClinicalTrials.gov registry record, October 2, 2026

  4. Regeneron registers trial of ALN-CIDEB in Metabolic Dysfunction-Associated Steatotic Liver Disease

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 1500 participants and plans to start on November 6, 2026, with primary completion on March 3, 2029.

    Source: ClinicalTrials.gov registry record, October 2, 2026

  5. PT Bio Farma registers Phase 3 trial of in-house recombinant Hepatitis B vaccine at birth dose

    This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 270 participants and has a planned start date of October 2026 with a planned primary completion date of February 2027.

    Source: ClinicalTrials.gov registry record, October 2, 2026

  6. GlaxoSmithKline registers phase 3 trial of mRNA seasonal influenza vaccine

    This study was first posted on ClinicalTrials.gov on October 1, 2026. The trial plans to enroll 3000 participants and aims to evaluate the immunogenicity, reactogenicity and safety of an mRNA-based seasonal influenza vaccine in adults 18-64 years of age.

    Source: ClinicalTrials.gov registry record, October 1, 2026

  7. Amgen registers Phase 3 study of inebilizumab in primary membranous nephropathy

    This study was first posted on ClinicalTrials.gov on October 1, 2026. The study plans to enroll 159 participants and aims to evaluate the efficacy of inebilizumab on PMN disease activity as measured by complete remission.

    Source: ClinicalTrials.gov registry record, October 1, 2026

  8. Novartis registers Phase IIIb trial of zigakibart + atrasentan in primary IgA nephropathy

    This study was first posted on ClinicalTrials.gov on September 30, 2026. The trial plans to enroll 340 participants and plans to start December 1, 2026.

    Source: ClinicalTrials.gov registry record, September 30, 2026

  9. Results posted for ABC008 study in inclusion body myositis

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 272 participants and completed primary data collection on November 6, 2025.

    Source: ClinicalTrials.gov results record, October 1, 2026

  10. Results posted for dexmedetomidine study in dementia agitation

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blind, placebo-controlled trial, enrolled 13 participants and was terminated.

    Source: ClinicalTrials.gov results record, October 1, 2026

  11. Results posted for SM04554 topical solution study in male androgenetic alopecia

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 675 participants and completed primary data collection on December 31, 2020.

    Source: ClinicalTrials.gov results record, October 1, 2026

  12. Results posted for Atacicept study in IgA nephropathy

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blinded, placebo-controlled trial (NCT04716231), enrolled 428 participants and began on June 29, 2023.

    Source: ClinicalTrials.gov results record, October 1, 2026

  13. Results posted for phase 3 orforglipron study in type 2 diabetes

    Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study enrolled 546 participants and completed primary data collection on September 15, 2025.

    Source: ClinicalTrials.gov results record, October 1, 2026

  14. Results posted for estradiol vaginal insert study

    Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 1050 participants and completed primary data collection on March 15, 2024.

    Source: ClinicalTrials.gov results record, September 30, 2026

  15. Results posted for TAK-881 PK, safety study in primary immunodeficiency diseases

    Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 65 participants and completed primary data collection on January 20, 2026.

    Source: ClinicalTrials.gov results record, September 30, 2026

  16. Results posted for LicartTM topical system study

    Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 151 participants, started on October 31, 2021, and completed primary data collection on June 30, 2024.

    Source: ClinicalTrials.gov results record, September 30, 2026

Regulation · 4

  1. EMA endorses ICMRA joint statement on animal testing alternatives

    EMA has endorsed a joint statement from the International Coalition of Medicines Regulatory Authorities (ICMRA) calling on medicine developers, manufacturers, regulators and national control laboratories to advance alternative methods to animal testing throughout the medicine lifecycle. The statement sets a long-term goal of replacing animal testing at all stages, from initial candidate screening to post-authorisation activities.

    Source: EMA news release, October 1, 2026

  2. EMA sets end-of-year submission dates for type I variations in 2026

    EMA advises marketing authorisation holders to submit type IA annual updates, individual type IA and type IA IN variations, and super-groupings no later than 20 November 2026. Submissions received after 20 November will still be processed, but the outcome may not be issued until January 2027.

    Source: EMA news release, October 1, 2026

  3. PRAC carries out safety assessment duties at its 28 September - 1 October meeting

    The Pharmacovigilance Risk Assessment Committee (PRAC) reviewed 9 safety signals, 85 periodic safety update reports, 49 risk management plans and 16 post-authorisation safety studies. No referral procedures were started, ongoing or concluded during the meeting.

    Source: EMA news release, October 2, 2026

  4. FDA classifies flushing and storage solution for vascular autografts at room temperature as class II

    The order places the device type into class II (special controls), which the FDA has determined will provide a reasonable assurance of the safety and effectiveness of the device. The FDA said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

    Source: Federal Register rule, September 30, 2026

Approvals · 1

  1. FDA approves pirtobrutinib for previously untreated CLL or SLL

    The FDA approved pirtobrutinib (Jaypirca, Eli Lilly and Company) on October 2, 2026 for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. The approval follows the BRUIN CLL-313 trial, which enrolled 282 patients and showed a median progression-free survival that was not estimable versus 33.5 months for bendamustine plus rituximab.

    Source: FDA approval notification, October 2, 2026